Still, shares fell by nearly 20% after the company revealed a delay in the coming launch of Revtorpyk. Details in the drug’s prescribing information surprised some analysts, too.
An article from
Still, shares fell by nearly 20% after the company revealed a delay in the coming launch of Revtorpyk. Details in the drug’s prescribing information surprised some analysts, too.
Published July 15, 2026
•
Sarah Silbiger via Getty Images
Correction to Celcuity Gets FDA Approval Headline
FDA approves Revtorpyk for hormone receptor-positive, HER2-negative breast cancer
With FDA approval for its breast cancer blockbuster hopeful, Celcuity could ‘belong in the hands’ of a Big Pharma
FDA approves breast cancer drug that cut progression risk by 76%
Celcuity's breast cancer drug approved, its first
FDA rejects Hengrui, Elevar’s PD-1 liver cancer combo for a 3rd time
Star Padcev-Keytruda combo expands bladder cancer reach with FDA approval, pressuring AstraZeneca
Gedatolisib could “establish a new standard of care” for PIK3CA-mutated breast cancer, an investigator said, but the results…
Celcuity's breast cancer drug received approval from the Food and Drug Administration. "Clecuity Gets FDA Approval for Breast…
The FDA has approved a new targeted therapy combination for the most common subtype of breast cancer.Gedatolisib (Revtorpyk,…
Celcuity stock crashed Tuesday on disappointing results for its three-drug approach to advanced breast cancer.
The FDA has approved a new | The FDA has approved a new small molecule inhibitor from Celcuity with blockbuster potential that…
Celcuity's gedatolisib doubled progression-free survival versus Novartis' Piqray in late-stage breast cancer, setting up a…
